Balaji Amines Ltd
Balaji Amines Ltd Q3 FY26 Results & Presentation Highlights: Revenue ₹331.30 Cr, PAT ₹30.76 Cr
Q3 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Balaji Amines Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Revenue from Operations for Q3FY26: ₹331.30 crore, compared to ₹320.59 crore in Q3FY25 (consolidated) and ₹304.68 crore in Q3FY25 (standalone). - Consolidated Q3FY26 Revenue growth YoY: 4.90%. - Standalone Q3FY26 Revenue growth YoY: 0.62%. - Total volumes for Q3FY26: 25,894 MT vs. EBITDA for Q3FY26 (Consolidated): ₹61.67 crore, up 15.12% YoY from ₹53.57 crore in Q3FY25 - EBITDA Margin for Q3FY26: 18.34%, up from 16.71% in Q3FY25 - Profit After Tax (PAT) for Q3FY26 (
From Balaji Amines Ltd's Q3 FY26 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Revenue from Operations for Q3FY26: ₹331.30 crore, compared to ₹320.59 crore in Q3FY25 (consolidated) and ₹304.68 crore in Q3FY25 (standalone).
- Consolidated Q3FY26 Revenue growth YoY: 4.90%.
- Standalone Q3FY26 Revenue growth YoY: 0.62%.
- Total volumes for Q3FY26: 25,894 MT vs. 24,097 MT in Q3FY25.
- Amines volumes Q3FY26: 6,993 MT.
- Amines Derivatives volumes Q3FY26: 9,223 MT.
- Specialty Chemicals volumes Q3FY26: 9,678 MT.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Balaji Amines Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Unit 4 Greenfield Capex Phases 2 & 3 to be completed by FY 2027, including increased capacity utilization.
- Dimethyl Ether (DME) plant of 100,000 TPA capacity under Phase 3 expansion; under erection; commissioning expected FY 2026-27.
- N-Methyl Morpholine (NMM) 5,000 TPA manufacturing facility under execution; commissioning expected FY 2026-27.
- PG Pharma Grade facility under execution; commissioning expected FY 2026-27.
- Acetonitrile (ACN) improved process plant under execution; commissioning expected FY 2026-27.
- Methylamines capacity expanded from 48,000 TPA to 88,000 TPA; latest tech plant commissioned Nov 10, 2024.
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Balaji Amines Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Balaji Amines Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹395 Cr, net profit ₹65 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Balaji Amines Ltd's management said in earlier quarters
- Q3 FY24 earnings call analysis →
- Q1 FY25 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q4 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
Others in Chemicals & Petrochemicals this season
- Vidhi Specialty Food Ingredients Ltd (Q3 FY26)
94.5 Cr, down 4.1% YoY from Rs. Key investor presentation takeaways from Vidhi Specialty Food Ingredients Ltd's Q3 FY26 investor presentation — and how it ranks
- Bodal Chemicals Ltd (Q3 FY26)
5,046.6 Mn, up 13.3% YoY (Q3 FY25: Rs. Key investor presentation takeaways from Bodal Chemicals Ltd's Q3 FY26 investor presentation — and how it ranks against s
- Chemcon Speciality Chemicals Ltd (Q3 FY26)
Q3 FY26 Revenue from Operations:** ₹57.3 Cr (vs ₹54.4 Cr in Q3 FY25) — approx. Key investor presentation takeaways from Chemcon Speciality Chemicals Ltd's Q3 FY
- Valiant Organics Ltd (Q3 FY26)
Q3-FY26 Consolidated Revenue from Operations: INR 1,593 Mn, down 14.8% YoY (Q3-FY25: INR 1,869 Mn) . Key investor presentation takeaways from Valiant Organics L
Frequently Asked Questions
What were Balaji Amines Ltd Q3 FY26 results?
Revenue from Operations for Q3FY26: ₹331.30 crore, compared to ₹320.59 crore in Q3FY25 (consolidated) and ₹304.68 crore in Q3FY25 (standalone). - Consolidated Q3FY26 Revenue growth YoY: 4.90%. - Standalone Q3FY26 Revenue growth YoY: 0.62%. - Total volumes for Q3FY26: 25,894 MT vs. EBITDA for Q3FY26 (Consolidated): ₹61.67 crore, up 15.12% YoY from ₹53.57 crore in Q3FY25 - EBITDA Margin for Q3FY26: 18.34%, up from 16.71% in Q3FY25 - Profit After Tax (PAT) for Q3FY26 (
What is Balaji Amines Ltd share price analysis?
Balaji Amines Ltd currently shows a neutral. The stock trades at a P/E of 34.5 with a market cap of ₹7,036 Cr. Investors should review the full earnings analysis for detailed insights.
Is Balaji Amines Ltd planning capital expenditure?
Unit 4 Greenfield Capex Phases 2 & 3 to be completed by FY 2027, including increased capacity utilization.
Keep Balaji Amines Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.